Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 25 recruiting now full pipeline

Trauma: full-pipeline trial registry

25 of 57 indexed Trauma trials are currently recruiting.

Corpus placement: #249 of 28,707 conditions by registered trial count.

57 US clinical trials · 25 currently recruiting · #249 of 28,707 conditions by registered trial count

Trauma: 57 US clinical trials tracked, 25 recruiting.

Trauma is the subject of 57 registered US clinical trials on ClinicalTrials.gov, 25 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 5 of these trials.

Enrollment posture brief

Registry condition trauma

OPEN 25 | RECR 44% | LATE 5 | EARLY 5 | RANK #249 | SPON 5

Nearest open-share peer: Small Lymphocytic Lymphoma (44% recruiting · 82 trials)

Sleep Disturbance56.1%Trauma (this)44%Anesthesia43.1%Diabetic Retinopathy25.9%Ocular Hypertension21.1%
Open-enrollment share among volume-matched conditions near Trauma

Trauma lists 25 open slots (44% of 57 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Trauma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Trauma is recruiting above its size-band peers.

    25 of 57 indexed trials (43.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Trauma trials is spread across many organizations.

    Massachusetts General Hospital accounts for 5 of 57 trials (8.8%). 47 distinct sponsors appear on at least one study for this condition label.

  3. Typical Trauma enrolment sits around 112 participants.

    Median target enrolment is 112 among the 57 trials that report a genuine target (sentinel values excluded). 25 of those (43.9%) plan for fewer than 100 participants.

  4. Trauma splits between interventional and observational designs.

    36 interventional and 21 observational studies make up this index (63.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 32Phase 43

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 2
Phase 4 3

Named interventions

Most-linked intervention names on Trauma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Quantra System Diagnostic test
2 trials
RBC units Biological
1 trials
11-gene set Other
1 trials
Life Steps and Sexual Decision-Making Behavioral
1 trials
CBT-TSC Behavioral
1 trials
Melatonin 5mg and Sleep Education Dietary supplement
1 trials
Nutrition supplement - Ensure shakes Dietary supplement
1 trials
Questionnaire self report Other
1 trials

US sites by state

Facility locations filed on Trauma trials. A trial with sites in several states counts in each.

Texas 12 trials
California 12 trials
Massachusetts 9 trials
Florida 7 trials
Ohio 6 trials
New York 6 trials
Colorado 5 trials
Washington 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Trauma page

57 registered trials, 25 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Trauma condition card totals 57 registered trials; most-linked intervention Quantra System; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.